FDA approves Medtronic's new cardiac systems featuring distance wireless telemetry

By Lisa Kerner

Erie, Pa., May 17 - The Food and Drug Administration has approved Medtronic, Inc.'s Concerto/Virtuoso line of implantable cardiac devices that help track and manage the symptoms of heart failure.

The approval coincides with Heart Rhythm 2006, the Heart Rhythm Society's 27th Annual Scientific Sessions, according to a company news release.

Both the Concerto cardiac resynchronization therapy-defibrillator (CRT-D) and Virtuoso implantable cardioverter defibrillator (ICD) are available with Medtronic's proprietary Conexus Wireless Telemetry, enabling communication between the implanted device and clinician programmers and patient home monitoring units.

"Implantable device therapy is entering a new era with innovation focused on overall cardiac disease management and enhancing patient quality of life," the director of Cardiac Electrophysiology, Arrhythmia and Pacing at Caritas St. Elizabeth's Medical Center in Boston, Charles Haffajee, said in the release.

"This system's features, in combination with wireless distance telemetry, offer more convenient, yet equally effective, device management and patient care."

Other features of the Concerto/Virtuoso line of cardiac devices include Conexus Wireless Telemetry with SmartRadio, OptiVol fluid status monitoring, left ventricular capture management and ATP during charging.

Medtronic is a medical technology company based in Minneapolis.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.